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Interleukin-1 (IL-l) is a monocyte-derived polypeptide hormone that interacts with a plasma membrane 
receptor. We have used oligonucleotide-directed mutagenesis to construct mutant human IL-1 proteins. 
Three different point mutants in a unique histidine residue (position 30) exhibited varying degrees ofreduced 
IL-l receptor binding affinity, whereas point mutants at five other residues behaved normally. Structural 
analysis of these mutant proteins by nuclear magnetic resonance spectroscopy detected no (or only minor) 
conformational changes relative to wild-type IL- 1. These data suggest that the unique histidine residue influ- 
ences the architecture of the receptor binding site on human IL-l. 
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1. INTRODUCTION 
Interleukin-1 (IL-l) refers to a family of 
monocyte-derived polypeptide hormones display- 
ing a wide range of biological activities including 
fever induction and augmentation of lymphocyte 
proliferation (reviews [ 1,2]). Recent cDNA cloning 
studies [3-51 have shown that IL-1 bioactivity can 
be mediated by 2 distinct 17 kDa molecules (IL-la 
and IL-l,@ each of which is produced by cleavage 
of a 31 kDa precursor. The existence of plasma 
membrane receptors for IL-l has been demon- 
strated by direct radiolabeled ligand binding 
studies [6-91 and the putative receptor has been 
recently identified by chemical cross-linking 
[6,7,10]. Despite their limited homology at the 
amino acid level (23%), it is now clear that IL-la 
and IL-l,& both compete for binding to the same 
receptor [7-lo]. It is therefore of interest to deter- 
mine the structural domains of the IL-la and 
IL-lb molecules that are involved in ligand bind- 
ing. Towards this end, we have used recombinant 
DNA technology to derive a series of point muta- 
tions in the IL-l,8 molecule. In this communica- 
tion, we show that three different substitutions of 
the unique histidine residue (position 30) result in 
mutant IL-l,8 molecules exhibiting varying degrees 
of reduced binding affinity for the IL-l receptor, 
whereas five substitutions at other amino acid 
residues have no effect. Analysis of these mutant 
proteins by nuclear magnetic resonance (NMR) 
spectroscopy further indicates that the His30 
substitutions do not detectably alter the overall 
conformation of the IL-l,8 molecule. These data 
raise the possibility that this unique histidine 
residue may contribute directly or indirectly to the 
molecular architecture of the receptor binding site 
on IL-lp. 
2. MATERIALS AND METHODS 
2.1. Cells 
A variant subline of murine EL4 thymoma cells 
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(designated EL4-6. I) was derived by mutagenesis 
and drug selection as described elsewhere [111. 
2.2. Preparation of IL-I@ mutants 
The procedure for introducing point mutations 
in the IL-l@ molecule via site directed mutagenesis 
has been described elsewhere [ 121. Mutant proteins 
were purified as described for the wild type protein 
1131. 
2.3, Nh4R spectroscopy 
Samples for NMR spectroscopy contained 1.4 to 
1.6 mM protein in DzO/sodium phosphate buffer 
(160-300 mM), sodium azide (3 mM), pH 7.5. All 
spectra were recorded on a Bruker AM 500 spec- 
trometer equipped with an Aspect 3000 computer 
at 25°C using a 90” observation pulse and employ- 
ing a 2 s relaxation delay. 64 transients obtained by 
quadrature detection with 8192 data points and a 
spectral width of 8.2 kHz were averaged for each 
spectrum. Prior to Fourier transformation the free 
induction decay was multiplied by an exponential 
equivalent o a line broadening of 1 Hz. Chemical 
shifts are quoted relative to 4,4-dimethylsila- 
pentane-1-sulfonate (DSS). 
2.4. Labeling of IL-I and receptor binding assay 
Recombinant human IL-la was radioiodinated 
according to the chloramine T method as described 
in detail elsewhere [9]. The radiolabeled ligand 
(‘2’I-IL-la) retained full biological activity as 
measured by its ability to induce the secretion of 
interleukin-2 (IL-2) in EL4-6.1 cells as well as in 
the thymocyte IL-l assay. The specific activity of 
‘251-IL-l was lo6 cpm/ng, 
125 Binding of I- IL-l to EL4-6.1 cells was carried 
out according to Dower et al. (6) with minor 
modifications [9]. Briefly, aliquots of 5 x lo5 
EL4-6.1 cells in 200 ~1 final volume were incubated 
with ‘2SI-IL-la for 3-4 h at 4°C to allow 
equilibrium binding. Bound and free radioactivity 
were then separated by centrifugation through an 
oil gradient. For competition binding experiments, 
various concentrations of unlabeled native (or mu- 
tant) IL- lp molecules were mixed with a fixed con- 
centration (usually 1 ng/ml) of 12’1-IL-l prior to 
addition of EL4-6.1 cells. Inhibition of ‘251-IL-lru 
binding was calculated as a percentage relative to 
binding in the absence of cold competitor (normal- 
ly 4000-7000 cpm). 
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3. RESULTS AND DISCUSSION 
The various point mutations of the human IL-lb 
molecule used in this study are indicated in table 1. 
In order to test the effect of these substitutions on 
the ability of the mutant IL-1 molecules to bind to 
the IL-l receptor, we made use of a recently 
described variant subline of EL4 thymoma cells 
(designated EL4-6.1) that responds in vitro to IL-l 
[14] and expresses large numbers (-20000 per cell) 
of membrane IL-l receptors [9]. As indicated in 
fig.lA, amino acid substitutions at positions 24, 
68, 71, 90 or 120/121 had no demonstrable ffect 
on IL-l binding in that the mutant molecules com- 
peted as well as intact IL-l@ for inhibition of 12’1- 
IL-la binding. (‘251-IL-la was used for these 
studies since it could be radioiodinated without 
loss of biological activity [9] and since it competes 
for binding with IL-l@.) In contrast, 3 different 
substitutions at the unique histidine residue (posi- 
tion 30 in the mature IL-l@ molecule) resulted in 
varying degrees of loss of binding activity (fig. 1B). 
Thus the replacement of His30 by Gln, Asn, or Arg 
led to reductions of approx. 2-fold, 30-fold, or 
lOO-fold, respectively, in competitive IL-l binding 
activity. 
The reduced receptor binding affinity of the 
histidine substitution mut~ts could imply that this 
residue contributes to the IL-l receptor binding 
site on IL- lp. Alternatively, these substitutions 
could result in major changes in IL-l,& conforma- 
tion. To address the latter issue, NMR spec- 
Table 1 
IL-l point mutations used in this study 
Amino acid Substitution Designation 
residuea 
Wild type Mutant 
24 Tyr Phe 1 
30 His Gln 2 
30 His Asn 3 
30 His Arg 4 
68 Tyr Phe 5 
71 CYs Ser 6 
90 T yr Phe 7 
120/121 Trp/Tyr Phe/Phe 8b 
a Refers to mature form of IL-1 molecule 
b Mutant 8 has 2 contiguous amino acid substitutions 
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Fig.1. Competition binding analysis of IL-l@ mutants. 
The indicated concentrations of unlabeled mutant (or 
control wild type) IL-l/3 were mixed at 4°C with ‘*-?- 
IL-la (1 ng/ml) prior to addition of EL4-6.1 cells (5 X 
lO’/tube). After 4 h at 4”C, bound radioactivity was 
evaluated by centrifugation of the cells through an oil 
gradient. Data are expressed as percent inhibition of 
L2’I-IL-1 binding as compared to untreated controls. (A) 
Mutants 1 (O), 5 (A), 6 (o), 7 (v) and 8 (0) are 
compared to wild type (+). (B) His mutants 2 (m), 3 (0) 
and 4 (v) are compared to wild type (+). Data in panel 
B represent mean values from 4 independent 
experiments. For convenience, mutants are numbered as 
in table 1. 
troscopy was performed on the three His30 
substitution mutants as well as the native IL-lfl 
protein. As shown in fig.2, no detectable dif- 
ferences in the 500 MHz proton NMR spectra were 
seen with the exception of the expected disap- 
pearance of His resonances in the aromatic region 
of the mutant spectra (8.19 and 7.12 ppm). Using 
two-dimensional homonuclear Hartmann-Hahn 
spectroscopy, similar through-bond cross-peaks 
were observed for IL-lfl and the three histidine 
mutants (not shown; see [12] for spectrum of 
His-Asn mutant). In studies to be reported 
elsewhere [12], the other five substitution mutants 
investigated in this study were likewise found not 
to differ dramatically from native IL-lfi in their 
NMR spectra, although the Tyr90 mutant showed 
the most distinct changes. 
Since proton NMR spectra are extremely sen- 
sitive to conformational changes in proteins [15], 
the spectral identity of IL-l@ and the three His30 
-Gin 
Fig.2. 500 MHz ‘H-NMR spectra of wild type IL-la and 
histidine substitution mutants at 25°C. Arrow indicates 
position of histidine resonance in wild type spectrum. 
substitution mutants essentially rules out major 
structural alterations as an explanation for the 
reduced binding affinity of the mutants. We 
therefore favor the hypothesis that His30 may con- 
tribute in some way to the receptor binding site on 
the IL-l,& molecule. In this context, we have 
previously shown [12] that this residue has an 
unusually high pKa (7.5) compared to free histidine 
or solvent accessible histidine in proteins (p& 
-6.5). Since a histidine residue with a high pK, is 
most likely involved in hydrogen bonding or salt 
bridge.formation, we propose that Hiss0 is respon- 
sible for a particular local protein conformation 
which in turn is important for IL-l receptor bind- 
ing. According to such a model, the hierarchy in 
receptor binding affinities exhibited by the three 
histidine substitution mutants (Gln > Asn > Arg) 
could be explained on the basis of steric com- 
patibility, since the NH2 group of glutamine could 
theoretically substitute more readily for the im- 
idazole side chain of histidine in hydrogen bon- 
ding, whereas asparagine and arginine side groups 
would be too short or long, respectively. 
Previous studies [16] have indicated that certain 
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proteolytic fragments of the IL-l,& molecule retain 
biological activity (as measured by induction of T 
lymphocyte proliferation), although the amino 
acid sequence (and consequent molecular localiza- 
tion) of these fragments was not reported. More 
recently, Rosenwasser et al. 1171 have described the 
expression of biologically active truncated IL-l,& 
molecules in transfected COS cells. Using this ap- 
proach, a peptide of 62 amino acids (corre- 
sponding to positions 20-81 of the mature IL-lfl 
molecule) retained detectable biological activity as 
measured by the induction of proliferation of 
thymocytes or cloned T helper cells, Signifi~ntly, 
this biologically active IL-I peptide includes the 
Hiss0 residue that we postulate to be important in 
receptor binding. 
Amino acid sequence analysis of human IL-la 
and IL-14 indicates that these proteins share only 
23% homology [5]. Nevertheless, competition 
binding studies [7-IO], including those described 
in this report, demonstrate directly that the cy and 
@ forms of human IL-l bind with comparable af- 
finity to the same plasma membrane receptor. In 
searching for a putative common receptor binding 
site on IL-Icy and IL-l,&, it is interesting to note 
that one of the three histidine residues of IL-la, 
like His30 of IL-lb, has an unusually high p& 
(7.5), whereas the two other histidine residues in 
IL-1~ titrate with p& values in the normal range. 
These results, while clearly indirect, raise the 
possibility that homologous IL-la and IL-la 
receptor binding sites may exist in the vicinity of 
these structurally homologous His residues. Direct 
testing of this hypothesis via mutation of the His 
residues of IL-lcu is currently in progress, 
ACKNOWLEDGEMENTS 
We wish to thank Anne-Lise Peitrequin and 
Francoise Besencon for expert technical assistance. 
REFERENCES 
[l] Dinarello, C.A. (1984) Rev. Infect. Dis. 6, 51-95. 
[2] Oppenheim, J.J., Kovacs, E.J., Matshushima, K.
and Durum, SK. (1986) Immunol. Today 7, 
45-56. 
131 
141 
151 
161 
171 
181 
WI 
1131 
1141 
1151 
1161 
u71 
Lomedico, P-T., Grubler, U., Heilman, C.P., 
Dukovich, M., Giri, J.G., Pan, Y.-C.E., Collier, 
K., Semoniow, R., Chua, A.O. and Mizel, S.B. 
(1984) Nature 312, 458-462. 
Auron, P.E., Webb, A.C., Rosenwasser, L.J., 
Mucci, SF., Rich, A., Wolff, S.M. and Dinarello, 
C.A. (1984) Proc. Natl. Acad. Sci. USA 81, 
7907-7911. 
March, C.J., Mosley, k., Larsen, A., Ceretti, 
D.P., Braedt, G., Price, V., Gillis, S., Henney, 
C.S., Kronheim, S.R., Grabstein, K., Conlon, 
P. J., Hopp, T.P. and Cosman, D. (1985) Nature 
315, 641-647. 
Dower, S.K., Kronheim, S.R., March, C.J., 
Confon, P. J., Hopp, T.P., Giliis, S. and Urdal, 
D.L. (1985) J. Exp. Med. 162, 501-515. 
Matsushima, K., Akahoshi, T., Yamada, M., 
Furutani, Y. and Oppenheim, J.J. (1986) J. 
lmmunol. 136, 4496-4502. 
Kilian, P.L., Kaffka, K.L., Stern, A.S., Woehle, 
D., Benjamin, W.R., Dechiara, T.M., Gubler, U., 
Farrar, J. J., Mizel, S.B. and Lomedico, P.T. 
(1986) J. Immunol. 146, 4509-4514. 
Lowenthal, J.W. and MacDonald, HR. (1986) J. 
Exp. Med., 164, 1060-1074. 
Dower, SK., Call, SM., Gillis, S, and Urdal, D.L. 
(1986) Proc. Natl. Acad. Sci. USA 83, 1060-1064. 
Zubler, R.H., Erard, F., Lees, R.K., Van Laer, 
M., Mingari, C., Moretta, L. and MacDonald, 
H.R. (1985) J. Immunol. 134, 3662-3668. 
Gronenborn, A.M., Clore, G.M., Schmeissner, U. 
and Wingfield, P. (1986) Eur. J. Biochem., in 
press. 
Wingfield, P., Payton, M., Tavernier, J., Barnes, 
M., Shaw, A., Rose, K., Simona, M.G., 
Demaczuk, S., Williamson, K. and Dayer, J.-M. 
(1986) Eur. J. Biochem., in press. 
Lowenthal, J.W., Cerottini, J.-C. and MacDonald, 
HR. (1986) J. Immunol., 137, 1226-1231. 
Jardetzky, 0. and Roberts, G.C.K. (1981) NMR in 
Molecular Biology, Academic Press, New York. 
Dinarello, C.A., Clowes, G.H.A., Gordon, A.H., 
Saravis, C.A. and Wolff, SM. (1984) J. Immunol. 
133, 1332-1338. 
Rosenwasser, L.J., Webb, AX., Clark, B.D., Irie, 
S., Chang, L., Dinarello, CA., Getrke, L., Wolff, 
S.M., Reich, A. and Auron, P.E. (1986) Proc. 
Natl. Acad. Sci. USA 83, 5243-5246. 
298 
